SuperworthCalidi Biotherapeutics EPS CLDI
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2026
- −$54.30
- Latest quarter, Q2 FY26
- −$2.94
- Fiscal year 2025
- −$111.59
Calidi Biotherapeutics' earnings per share was −$54.30 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$2.94.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$111.59 | n/a |
| FY2024 | −$833.44 | n/a |
| FY2023 | −$4890.24 | n/a |
| FY2021 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$2.94 | n/a | −$54.30 | |
| Q1 FY26 | −$6.88 | n/a | −$83.11 | |
| Q4 FY25 | −$9.12 | n/a | −$111.59 | |
| Q3 FY25 | −$35.36 | n/a | −$154.15 | |
| Q2 FY25 | −$31.75 | n/a | −$242.79 | |
| Q1 FY25 | −$35.36 | n/a | −$479.04 | |
| Q4 FY24 | −$51.68 | n/a | −$833.44 | |
| Q3 FY24 | −$124.00 | n/a | −$1227.20 | |
| Q2 FY24 | −$268.00 | n/a | −$1373.92 | |
| Q1 FY24 | −$389.76 | n/a | −$3840.00 | |
| Q4 FY23 | −$445.44 | n/a | −$4890.24 | |
| Q3 FY23 | −$270.72 | n/a | n/a |
Against its peers
Companies in Healthcare nearest Calidi Biotherapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CLDICalidi Biotherapeutics | −$54.30 | |
| OXBROXBRIDGE RE HOLDINGS | $0.02 | |
| EDUCEducational Development | $0.19 | |
| GTIMGood Times Restaurants | $0.21 | +75% a year |
| MDRRMedalist Diversified | $3.84 | |
| Peer median | $0.20 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Calidi Biotherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.